Loading...
Market
How many RNA drugs will Judo Bio develop using STRIKE by 2027?
3
Resolution / Starting Odds
1 drug • 25%
2 drugs • 25%
3 drugs • 25%
4 or more drugs • 25%
Company announcements or drug pipeline updates
Story
Judo Bio Launches with $100M to Develop RNA Kidney Drugs Using STRIKE Platform
Oct 7, 2024, 12:16 PM
Judo Bio has debuted with a $100 million launch, aiming to develop RNA drugs targeting the kidney. The company plans to utilize its Selectively Targeting RNA Into KidnEy (STRIKE) platform to develop ligand-siRNA conjugates. The launch comes less than two months after Borealis Bio's $150 million launch for similar RNA kidney drugs. Judo Bio's leadership includes CEO Rajiv Patni and CSO Alfica Sehgal, with backing from Atlas Venture and TCG. The company is taking a page from Alnylam's playbook and is part of the broader startups ecosystem.
View original story
Similar markets
None • 25%
1-3 targets • 25%
4-6 targets • 25%
More than 6 targets • 25%
None • 33%
One • 33%
Two or more • 33%
Wave Life Sciences • 25%
ProQR Therapeutics • 25%
Korro Bio • 25%
Other • 25%
10-12 • 25%
13-15 • 25%
16-18 • 25%
19 or more • 25%
0-1 • 25%
2-3 • 25%
4-5 • 25%
More than 5 • 25%
Wave Life Sciences • 25%
ProQR Therapeutics • 25%
Korro Bio • 25%
Other • 25%
1-3 drugs/vaccines • 25%
4-6 drugs/vaccines • 25%
7-9 drugs/vaccines • 25%
10 drugs/vaccines • 25%
Wave Life Sciences • 33%
ProQR Therapeutics • 33%
Caribou Biosciences • 33%
Other • 1%
More than 3 new drugs • 25%
2-3 new drugs • 25%
1 new drug • 25%
No new drugs • 25%
Full agreement executed • 25%
Partial execution • 25%
Agreement terminated • 25%
No significant progress • 25%
Clinical trial initiation • 25%
Regulatory approval • 25%
New program announcement • 25%
No major milestone • 25%